ATS(US:ATS)2024-02-07 13:24Financial Performance - Q3 2024 revenues increased by approximately 16% year-over-year to $752 million[8, 11] - Q3 2024 adjusted earnings from operations increased by approximately 17% year-over-year to $1012 million, with a 135% adjusted earnings from operations margin, up 13 bps year-over-year[8, 11] - Q3 2024 EBITDA increased by $298 million to $1137 million, a 355% increase year-over-year[11] - Q3 2024 adjusted EBITDA increased by $186 million to $1193 million, a 185% increase year-over-year[11] - Q3 2024 net income increased by $18 million to $472 million, a 616% increase year-over-year[11] - Q3 2024 basic earnings per share increased by $016 to $048, a 50% increase year-over-year[11] - Q3 2024 adjusted basic earnings per share increased by $009 to $065, a 161% increase year-over-year[11] Order and Backlog - Q3 2024 order bookings decreased by approximately 32% year-over-year to $668 million, which included $221 million USD EV Order Bookings (approximately $3002 million CAD)[8] - Order backlog of $1907 million provides good revenue visibility[8] - Estimated Q4 F24 order backlog-to-revenue conversion is 36% to 39%[11, 13] Market Outlook - Life Sciences order backlog is $875 million, with a strong funnel focused on strategic areas[9] - Transportation order backlog is $564 million, including approximately $200 million on delayed projects, with strong funnel and long-term fundamentals[9]